https://seekingalpha.com/article/4762166-allogene-assessing-the-pipeline-competitive-landscape-and-opportunities [Seeking Alpha]
Allogene Therapeutics, Inc. (ALLO)
Last allogene therapeutics, inc. earnings: 2/27 04:30 am
Check Earnings Report
Company Research
Source: Seeking Alpha
Cema-cel, Allogene's leading product, shows promise in first-line treatment of large B-cell malignancies, with significant revenue potential and positive clinical trial results. Allogene's financial health is stable, with a cash runway until Q1, 2026, and the company is rated a "Buy" for long-term, high-risk-tolerant investors. Key upcoming catalysts include interim data for Cema-cel's ALPHA3 by mid-2025, and initial trials for ALLO-329 in autoimmune diseases starting in H1, 2025. Nemes Laszlo/iStock via Getty Images Overview Allogene Therapeutics, Inc. NASDAQ: ALLO ) is pioneering the development of allogeneic chimeric antigen receptor T-cells (CAR-Ts) for the treatment of cancer and autoimmune diseases. In other words, Allogene is genetically modifying
Read more
Impact Snapshot
Event Time:
ALLO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALLO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALLO alerts
High impacting Allogene Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ALLO
News
- Allogene Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business UpdateGlobeNewswire
- Foresight Diagnostics Expands Strategic Partnership with Allogene Therapeutics to Advance Joint Development Activities Outside of the U.S. Across Europe, UK, Canada and Australia [Yahoo! Finance]Yahoo! Finance
- Allogene Therapeutics Announces Participation in March Investor ConferenceGlobeNewswire
- Allogene Therapeutics Expands Strategic Partnership with Foresight Diagnostics to Advance Joint Development Activities Outside the US Across Europe, UK, Canada, and AustraliaGlobeNewswire
- Allogene Therapeutics Announces Publication of Durable Response Data from Phase 1 ALPHA/ALPHA2 Trials of the Allogeneic CAR T Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma in the Journal of Clinical Oncology [Yahoo! FinYahoo! Fin
ALLO
Earnings
- 11/7/24 - Beat
ALLO
Sec Filings
- 3/7/25 - Form SCHEDULE
- 3/5/25 - Form 4
- 3/4/25 - Form 3
- ALLO's page on the SEC website